thymic-factor--circulating and Intestinal-Diseases

We have previously reported that a nonapeptide thymic hormone, facteur thymique serique (FTS), is involved in the differentiation and activation of intestinal intraepithelial lymphocytes (i-IEL) in mice. In this study, we examined the effect of FTS treatment on enteropathy in a murine model for acute graft-vs.-host disease (GVHD) induced by injection of parental C57BL/6 splenocytes into unirradiated (C57BL/6 x DBA/2) F1 hybrids. FTS treatment significantly protected mice from developing acute GVHD as assessed by mortality rate, splenomegaly and enteropathy. The infiltration of donor-derived TCR alpha beta i-IEL bearing CD8 alpha beta was significantly inhibited in the small intestine of FTS-treated mice, and the frequencies of apoptosis of crypt cells in the intestinal mucosa were decreased in these mice during acute GVHD. These results suggest that FTS treatment contributes to protection against enteropathy of acute GVHD. Thus, FTS may provide a useful approach to control acute GVHD after blood transfusion or bone marrow transplantation.

Topics: Animals; Apoptosis; Female; Flow Cytometry; Graft vs Host Disease; Intestinal Diseases; Intestinal Mucosa; Intestine, Small; Lymphocytes; Mice; Mice, Inbred C57BL; Splenomegaly; Thymic Factor, Circulating; Tissue Donors

Topics: Acute Disease; Adjuvants, Immunologic; Adolescent; Adult; Combined Modality Therapy; Drug Evaluation; Dysentery, Bacillary; Humans; Intestinal Diseases; Male; Shigella flexneri; Shigella sonnei; Thymus Hormones; Typhoid Fever